多西他赛联合卡培他滨化疗治疗进展期胃癌术后的研究

Study on docetaxel plus capecitabine in treatment of advanced gastric carcinoma postoperation

目的探讨进展期胃癌根治术后予以多西他赛联合卡培他滨化疗的疗效及耐受性。方法 126例进展期胃癌根治术后患者随机分为2组,试验组63例采用多西他赛(TXT)+卡培他滨方案化疗,对照组63例采用TXT+奥沙利铂+5-氟尿嘧啶/CF方案化疗,比较2组的不良反应发生率及1 a、3 a生存率。结果试验组1 a及3 a生存率分别为81%和62%,对照组分别为60%和38%,2组1 a及3 a生存率比较均有显著性差异(P均<0.05)。试验组不良反应发生率为76%,对照组为44%,2组比较无显著性差异(P>0.05)。结论进展期胃癌根治术后采用TXT联合卡培他滨方案化疗能显著提高患者的1 a及3 a生存率,且患者容易耐受。

Objective It is to investigate the curative effect and toleration of docetaxel plus capecitabine in the treatment of advanced gastric carcinoma post-operation.Methods 126 patients with advanced gastric carcinoma after radical gastrectomy were randomly divided into two groups： 63 cases in test group were received docetaxel plus capecitabine chemotherapy;63 cases in control group were received docetaxel plus L-OHP and 5-FU/CF chemotherapy.The side effect and 1-and 3-year survival rates were compared between both groups.Results 1-and 3-year survival rate was 81%,62% in test group,and 60%,38% in control group respectively,there was significantly difference between both groups（P0.05）.The side effect rate in test group was 76%,and 44% in control group.There was no significant difference between both groups（P0.05）.Conclusion Postoperative docetaxel plus capecitabine chemotherapy can improve 1-and 3-year survival rates in patients with advanced gastric carcinoma,and the side effect of chemotherapy is well tolerable.